Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Cabel

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
JAMA Network Open|December 15, 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival OutcomesMarcela Carausu, Matthieu Carton, Véronique Diéras, et al.
British Journal of Cancer|October 7, 2022
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutationsWilliam Jacot, Amélie Lusque, Cécile Vicier, et al.
Radiology|September 3, 2024
Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapyToulsie Ramtohul, Victoire Lepagney, Claire Bonneau, et al.
NPJ Breast Cancer|February 13, 2025
Clinico-pathological factors predicting pathological response in early triple-negative breast cancerClara Helal, Lounes Djerroudi, Toulsie Ramtohul, et al.
Radiology|July 1, 2025
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapyToulsie Ramtohul, Derek Lollivier, Justine Spriet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized TrialFrançois-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell CarcinomaLuc Cabel, Emmanuelle Jeannot, Ivan Bieche, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
Angiogenesis|November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Oncogene|November 4, 2022
Microsatellite instability detection in breast cancer using drop-off droplet digital PCRKhadidja Zeyneb Klouch, Marc-Henri Stern, Olfa Trabelsi-Grati, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
JAMA Network Open|December 15, 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival OutcomesMarcela Carausu, Matthieu Carton, Véronique Diéras, et al.
British Journal of Cancer|October 7, 2022
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutationsWilliam Jacot, Amélie Lusque, Cécile Vicier, et al.
Radiology|September 3, 2024
Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapyToulsie Ramtohul, Victoire Lepagney, Claire Bonneau, et al.
NPJ Breast Cancer|February 13, 2025
Clinico-pathological factors predicting pathological response in early triple-negative breast cancerClara Helal, Lounes Djerroudi, Toulsie Ramtohul, et al.
Radiology|July 1, 2025
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapyToulsie Ramtohul, Derek Lollivier, Justine Spriet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized TrialFrançois-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell CarcinomaLuc Cabel, Emmanuelle Jeannot, Ivan Bieche, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
Angiogenesis|November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Oncogene|November 4, 2022
Microsatellite instability detection in breast cancer using drop-off droplet digital PCRKhadidja Zeyneb Klouch, Marc-Henri Stern, Olfa Trabelsi-Grati, et al.
Pageof 8